Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 142   

Articles published

NVS 100.07 +0.06 (0.06%)
price chart
Novartis AG (ADR) (NYSE:NVS) Leading the Way for Cancer Treatments
Novartis AG (ADR) (NYSE:NVS), the pioneer in research and development in the field of healthcare products, reported on Friday that its new drug Zykadia, for cancer treatment, has now been approved by the European Medicines Agency's Committee for ...
GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS) announced on Monday that the two companies have completed a series of complicated asset swaps worth $20 billion, in what appears to be a move to tidy up asset portfolios to ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) Update: GlaxoSmithKline sees Novartis ...  Ashburn Daily
Novartis AG (ADR) (NYSE:NVS)'s Farydak Gets Approval From FDA
Novartis AG (ADR) (NYSE:NVS)'s multiple myeloma treatment Farydak received FDA approval, despite an advisory panel's recommendation against approval.
Company Shares of Novartis AG (ADR) Rally 0.39%  Ashburn Daily
Price Target Update on Novartis AG (ADR)  Markets Bureau
Novartis AG (ADR) Ordered To Halt Some Japanese Operations
The Japanese Health Ministry has ordered Novartis AG ADR (NYSE: NVS) to halt most of its operations in Japan for 15 days in March, claiming that the company had failed to report side-effects caused by its products within a pre-specified time.
GlaxoSmithKline plc (ADR) To Close Asset Swap Deal With Novartis AG (ADR ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced on Wednesday that it anticipates closing the mega-billion dollar asset exchange with Novartis AG (ADR) (NYSE:NVS) in the week beginning March 2, 2015. However, the deal, which is expected to make ...
Novartis AG (ADR) Lung Cancer Drug Wins EU Recommendation
Novartis AG (ADR) (NYSE:NVS), a world leader in the research and development of healthcare products, announced Friday that its novel advanced lung cancer drug, Zykadia, has won recommendation from the European Medicines Agency's Committee for ...
Novartis AG (ADR) Wins FDA Approval For Blood Cancer Drug
Novartis AG (ADR) (NYSE: NVS) has won the US Food and Drug Administration's (FDA) approval for its new blood-cancer treatment drug, Farydak.
Novartis AG (ADR) (NYSE:NVS) Update: FDA approves Farydak for treatment of ...  Markets Bureau
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
We are impressed by Novartis' efforts to realign its portfolio in order to focus on its core portfolio of pharmaceuticals, eye care and generics. The agreement to acquire oncology products from Glaxo will further broaden Novartis' portfolio, enable it ...
Related articles »  
Trouble For Novartis AG (ADR) (NVS) In Japan
Novartis AG (ADR) (NYSE:NVS) faces temporary suspension of its commercial activities in Japan as penalty for alleged manipulation of clinical trial data related to its blood pressure drug Diovan.
Firm Rating Update on Novartis AG (ADR)  Stafford Daily
Share Price of Novartis AG (ADR) Rally 3.49%
Investors in Novartis AG (NVS) found the counter bleeding as the shares closed down 0.1661% or 0.17 points. The trading commenced at 101.99 and the shares soon toppled to hit a low of 101.73.